The impact of preimplantation genetic testing on prenatal diagnostic procedures

Abstract

Objective

In recent years, cell-free DNA screening has significantly reduced the number of invasive prenatal diagnostic testing in pregnancy. Preimplantation genetic testing for aneuploidies (PGT-A) is a commonly performed screening test in in vitro fertilization (IVF) pregnancies. Therefore, we aimed to determine the impact of PGT-A on subsequent utilization of prenatal diagnostic testing in IVF pregnancies.

Methods

Retrospective cohort of singleton and twin IVF pregnancies at a single center from January 2014 to December 2017. The rate of invasive diagnostic genetic testing (chorionic villus sampling (CVS) and/or amniocentesis) was compared between patients with pregnancies achieved after transfer of a euploid embryo by PGT-A (n = 71) and those with pregnancies achieved after transfer of an untested embryo (n = 38). Wilcoxon rank sum and Fisher’s exact tests were used for statistical analysis.

Results

There was no statistically significant difference in the number of prenatal diagnostic procedures (25.4% PGT-A euploid embryo versus 31.6% untested embryo, p = .51 and p = .32 for one-sided and two-sided analyses, respectively) between the two groups. Maternal age, nuchal translucency measurements and the rate of abnormal sonographic findings were similar between the two groups. Patients without PGT-A pregnancies had a higher BMI (mean 29.6, p = .01) and were ethnically different (p = .013) compared to those with PGT-A.

Conclusion

The implementation of PGT-A in IVF patients did not reduce the number of invasive diagnostic tests performed at our institution.

Keywords:

• Amniocentesis
• chorionic villus sampling
• preimplantation genetic testing for aneuploidies
• prenatal diagnosis

Disclosure statement

No potential conflict of interest was reported by the authors.